Enveric Biosciences, Inc. (ENVB) Cash Flow Statement

The persistent gap between net income and operating cash flow suggests that the company's losses are not merely accounting artifacts but represent actual cash depletion. Investors should monitor the fact that operating cash flow remains negative in every period, confirming that the business model has yet to achieve any form of operational self-sufficiency.

The absence of positive free cash flow margins underscores the speculative nature of the company's current development stage. This trajectory suggests that without a significant shift toward licensing revenue, the firm will continue to face structural cash flow challenges that may limit its strategic flexibility.

These fluctuations appear to be driven by the timing of research-related payments rather than efficient inventory or receivables management. Such volatility warrants further investigation, as it complicates the predictability of the company's cash runway and suggests that management has limited control over the timing of its cash outflows.